38856
document
Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours . The efficacy of pegfilgrastim+/-chemotherapy for mobilizing stem cells in patients with solid tumours was assessed . In cycle 0 , a 14-day prechemotherapy cycle , patients ( N=61 ) were randomized open-label to single doses of pegfilgrastim ( 6 , 12 or 18 mg ) on day 1 , or daily filgrastim ( 10 microg/kg ) for < or =7 days . Mean peak peripheral CD34+ cell counts increased with pegfilgrastim dose , but were significantly higher than filgrastim only at the 18 mg dose ( 10.17 vs 4.96 x 10 ( 4 ) /ml ; P=0.014 ) . In the clinically relevant period of days 3-7 , both 12 and 18 mg pegfilgrastim doses produced significantly higher peak CD34+ counts ( 8.18 and 9.96 vs 4.51 x 10 ( 4 ) /ml for filgrastim ; P=0.034 and 0.006 ) . In cycle 1 , patients received carboplatin/paclitaxel on day 1 , followed from day 2 by pegfilgrastim 6-18 mg or daily filgrastim ( 5 microg/kg/day for < or =14 days ) as per randomization in cycle 0 . There were no significant differences in mean peak CD34+ count between pegfilgrastim and filgrastim , but there was an advantage for pegfilgrastim 18 mg in the relevant period of days 7-12 ( 3.14 vs 1.19 x 10 ( 4 ) /ml ; P=0.043 ) . A single pegfilgrastim dose ( > or =6 mg ) could be substituted for daily filgrastim in cytokine-only peripheral CD34+ cell mobilization .
38857
Intervention_Pharmacological
Pegfilgrastim
38858
Intervention_Pharmacological
pegfilgrastim+/-chemotherapy
38859
Intervention_Pharmacological
pegfilgrastim
38860
Intervention_Pharmacological
filgrastim
38861
Intervention_Pharmacological
pegfilgrastim
38862
Intervention_Pharmacological
filgrastim
38863
Intervention_Pharmacological
pegfilgrastim
38864
Intervention_Pharmacological
filgrastim
38865
Intervention_Pharmacological
carboplatin/paclitaxel
38866
Intervention_Pharmacological
pegfilgrastim
38867
Intervention_Pharmacological
filgrastim
38868
Intervention_Pharmacological
pegfilgrastim
38869
Intervention_Pharmacological
filgrastim
38870
Intervention_Pharmacological
pegfilgrastim
38871
Intervention_Pharmacological
pegfilgrastim
38872
Intervention_Pharmacological
filgrastim
38873
Outcome_Other
efficacy
38874
Outcome_Physical
Mean peak peripheral CD34+ cell counts
38875
Outcome_Other
significantly higher
38876
Outcome_Physical
significantly higher peak CD34+ counts
38877
Outcome_Other
no significant differences
38878
Outcome_Physical
mean peak CD34+ count
38879
Outcome_Physical
cytokine-only peripheral CD34+ cell mobilization .
38880
Participant_Condition
patients with solid tumours
38881
Participant_Condition
solid tumours
38882
Participant_Sample-size
patients ( N=61 )